Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Neuromolecular Med. 2011 Jun;13(2):93-116. doi: 10.1007/s12017-010-8140-8. Epub 2010 Dec 17.
The aim of this review is to evaluate the evidentiary base supporting the hypothesis that the increased hazard for obesity in mood disorder populations (and vice versa) is a consequence of shared pathophysiological pathways. We conducted a PubMed search of all English-language articles with the following search terms: obesity, inflammation, hypothalamic-pituitary-adrenal axis, insulin, cognition, CNS, and neurotransmitters, cross-referenced with major depressive disorder and bipolar disorder. The frequent co-occurrence of mood disorders and obesity may be characterized by interconnected pathophysiology. Both conditions are marked by structural and functional abnormalities in multiple cortical and subcortical brain regions that subserve cognitive and/or affective processing. Abnormalities in several interacting biological networks (e.g. immuno-inflammatory, insulin signaling, and counterregulatory hormones) contribute to the co-occurence of mood disorders and obesity. Unequivocal evidence now indicates that obesity and mood disorders are chronic low-grade pro-inflammatory states that result in a gradual accumulation of allostatic load. Abnormalities in key effector proteins of the pro-inflammatory cascade include, but are not limited to, cytokines/adipokines such as adiponectin, leptin, and resistin as well as tumor necrosis factor alpha and interleukin-6. Taken together, the bidirectional relationship between obesity and mood disorders may represent an exophenotypic manifestation of aberrant neural and inflammatory networks. The clinical implications of these observations are that, practitioners should screen individuals with obesity for the presence of clinically significant depressive symptoms (and vice versa). This clinical recommendation is amplified in individuals presenting with biochemical indicators of insulin resistance and other concurrent conditions associated with abnormal inflammatory signaling (e.g. cardiovascular disease).
本综述的目的是评估支持以下假说的证据基础,即心境障碍人群中肥胖风险增加(反之亦然)是共同病理生理途径的结果。我们使用以下搜索词在 PubMed 上进行了所有英文文章的搜索:肥胖、炎症、下丘脑-垂体-肾上腺轴、胰岛素、认知、中枢神经系统和神经递质,并与重性抑郁障碍和双相情感障碍交叉引用。心境障碍和肥胖的频繁共病可能以相互关联的病理生理学为特征。这两种情况都以多个皮质和皮质下脑区的结构和功能异常为特征,这些脑区负责认知和/或情感处理。几个相互作用的生物网络(例如免疫炎症、胰岛素信号和代偿性激素)的异常导致心境障碍和肥胖的共病。现在明确的证据表明,肥胖和心境障碍是慢性低度炎症状态,导致全身性适应负荷逐渐积累。促炎级联的关键效应蛋白异常包括但不限于细胞因子/脂肪因子,如脂联素、瘦素和抵抗素以及肿瘤坏死因子-α和白细胞介素-6。总之,肥胖和心境障碍之间的双向关系可能代表异常神经和炎症网络的外显型表现。这些观察结果的临床意义是,临床医生应该筛查肥胖个体是否存在临床显著的抑郁症状(反之亦然)。对于存在胰岛素抵抗和其他与异常炎症信号相关的并存情况(例如心血管疾病)的生化指标的个体,应放大这一临床建议。